Immunotherapy with myeloid cells for tolerance induction

Current Opinion in Organ Transplantation

Volumn 15, Issue 4, 2010, Pages 416-421

  Rodriguez García, Mercedes ^a   Boros, Peter ^b   Bromberg, Jonathan S ^c   Ochando, Jordi C ^a,c  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Department of Surgery ^*  (Australia)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

immunotherapy; myeloid dendritic cells; regulatory T cells

Indexed keywords

ACETYLSALICYLIC ACID; AROMATIC HYDROCARBON RECEPTOR; B7 ANTIGEN; BONE MORPHOGENETIC PROTEIN 4; CD123 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; COLECALCIFEROL; CYCLOSPORIN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEXAMETHASONE; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; LYMPHOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID; PROSTAGLANDIN; RAPAMYCIN; STEM CELL FACTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGRAFT; ANTIGEN SPECIFICITY; BONE MARROW CELL; CD25+ T LYMPHOCYTE; CELL INTERACTION; CELL PROLIFERATION; CELLULAR IMMUNITY; EMBRYONIC STEM CELL; GRAFT SURVIVAL; HUMAN; IMMUNOTHERAPY; MYELOID DENDRITIC CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SKIN GRAFT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TRANSPLANTATION TOLERANCE; ANIMAL; CELL CULTURE; CULTURE TECHNIQUE; DENDRITIC CELL; DRUG EFFECTS; GRAFT REJECTION; IMMUNOLOGY; PROCEDURES; TRANSPLANTATION;

ANIMALS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; DENDRITIC CELLS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOTHERAPY; MYELOID CELLS; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE;

EID: 77955231434     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32833bcf5e     Document Type: Review

References (76)

1. Wood KJ, Bushell AR, Jones ND. The discovery of immunological tolerance: now more than just a laboratory solution. J Immunol 2010; 184:3-4.
2. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419-426.
3. Buckland M, Lombardi G. Aspirin and the induction of tolerance by dendritic cells. Handb Exp Pharmacol 2009; 197-213.
4. Torres-Aguilar H, Aguilar-Ruiz SR, Gonzalez-Perez G, et al. Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4+ T cells. J Immunol 2010; 184:1765-1775.
5. Delgado M. Generating tolerogenic dendritic cells with neuropeptides. Hum Immunol 2009; 70:300-307.
6. Tan PH, Yates JB, Xue SA, et al. Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression. Blood 2005; 106:2936-2943.
7. Xiang J, Gu X, Zhou Y, et al. Administration of dendritic cells modified by RNA interference prolongs cardiac allograft survival. Microsurgery 2007; 27:320-323.
8. Turnquist HR, Raimondi G, Zahorchak AF, et al. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178:7018-7031.
9. Zahorchak AF, Kean LS, Tokita D, et al. Infusion of stably immature monocytederived dendritic cells plus CTLA4Ig modulates alloimmune reactivity in rhesus macaques. Transplantation 2007; 84:196-206.
10. Taner T, Hackstein H, Wang Z, et al. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce age-specific T cell regulation and prolong graft survival. Am J Transplant 2005; 5:228-236.
11. Horibe EK, Sacks J, Unadkat J, et al. Rapamycin-conditioned, alloantigenpulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transpl Immunol 2008; 18:307-318.
12. Cobbold SP, Adams E, Farquhar CA, et al. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci USA 2009; 106:12055-12060.
13. Lagaraine C, Lemoine R, Baron C, et al. Induction of human CD4+ regulatory T cells by mycophenolic acid-treated dendritic cells. J Leukoc Biol 2008; 84:1057-1064.
14. Geng L, Dong S, Fang Y, et al. Cyclosporin a up-regulates B7-DC expression on dendritic cells in an IL-4-dependent manner in vitro, which is associated with decreased allostimulatory capacity of dendritic cells. Immunopharmacol Immunotoxicol 2008; 30:399-409.
15. Bosma BM, Metselaar HJ, Nagtzaam NM, et al. Dexamethasone transforms lipopolysaccharide-stimulated human blood myeloid dendritic cells into myeloid dendritic cells that prime interleukin-10 production in T cells. Immunology 2008; 125:91-100.
16. Hamdi H, Godot V, Maillot MC, et al. Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper. Blood 2007; 110:211-219.
17. Fazekasova H, Golshayan D, Read J, et al. Regulation of rat and human T-cell immune response by pharmacologically modified dendritic cells. Transplantation 2009; 87:1617-1628.
18. Stax AM, Gelderman KA, Schlagwein N, et al. Induction of donor-specific Tcell hyporesponsiveness using dexamethasone-treated dendritic cells in two fully mismatched rat kidney transplantation models. Transplantation 2008; 86:1275-1282.
19. Zeng M, Guinet E, Nouri-Shirazi M. Comparative analysis of dendritic cells and anti-CD3/CD28 expanded regulatory T cells for application in transplantation. Transpl Immunol 2009; 22:82-92.
20. Unger WW, Laban S, Kleijwegt FS, et al. Induction of Treg by monocytederived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol 2009; 39:3147-3159.
21. Anderson AE, Swan DJ, Sayers BL, et al. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukoc Biol 2009; 85:243-250.
22. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192:1213-1222.
23. Peche H, Trinite B, Martinet B, Cuturi MC. Prolongation of heart allograft survival by immature dendritic cells generated from recipient type bone marrow progenitors. Am J Transplant 2005; 5:255-267.
24. Jeffery LE, Burke F, Mura M, et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009; 183:5458-5467.
25. Fu F, Li Y, Qian S, et al. Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation 1996; 62:659-665.
26. Hauben E, Gregori S, Draghici E, et al. Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. Blood 2008; 112:1214-1222.
27. Lutz MB, Suri RM, Niimi M, et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 2000; 30:1813-1822.
28. Chitta S, Santambrogio L, Stern LJ. GMCSF in the absence of other cytokines sustains human dendritic cell precursors with T cell regulatory activity and capacity to differentiate into functional dendritic cells. Immunol Lett 2008; 116:41-54.
29. Eljaafari A, Li YP, Miossec P. IFN-gamma, as secreted during an alloresponse, induces differentiation of monocytes into tolerogenic dendritic cells, resulting in FoxP3+ regulatory T cell promotion. J Immunol 2009; 183:2932-2945.
30. Feng G, Gao W, Strom TB, et al. Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells. Eur J Immunol 2008; 38:2512-2527.
31. Feng G, Wood KJ, Bushell A. Interferon-gamma conditioning ex vivo generates CD25+CD62L+Foxp3+ regulatory T cells that prevent allograft rejection: potential avenues for cellular therapy. Transplantation 2008; 86:578-589.
32. Fu BM, He XS, Yu S, et al. A tolerogenic semimature dendritic cells induce effector T-cell hyporesponsiveness by activation of antigen-specific CD4+CD25+ T regulatory cells that promotes skin allograft survival in mice. Cell Immunol 2010; 261:69-76.
33. Dai H, Zhu H, Lei P, et al. Programmed death-1 signaling is essential for the skin allograft protection by alternatively activated dendritic cell infusion in mice. Transplantation 2009; 88:864-873.
34. Raimondi G, Sumpter TL, Matta BM, et al. Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. J Immunol 2010; 184:624-636.
35. Darrasse-Jeze G, Deroubaix S, Mouquet H, et al. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med 2009; 206:1853-1862.
36. SacksJM,KuoYR,TaiebA,et al.Prolongationofcompositetissueallograftsurvival by immature recipientdendritic cells pulsed withdonor antigen andtransient lowdose immunosuppression. Plast Reconstr Surg 2008; 121:37-49.
37. Moreau A, Hill M, Thebault P, et al. Tolerogenic dendritic cells actively inhibit T cells through heme oxygenase-1 in rodents and in nonhuman primates. FASEB J 2009; 23:3070-3077.
38. Pozo D, Anderson P, Gonzalez-Rey E. Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide. J Immunol 2009; 183: 4346-4359.
39. Gonzalez-Rey E, Chorny A, Fernandez-Martin A, et al. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood 2006; 107:3632-3638.
40. Chorny A, Gonzalez-Rey E, Fernandez-Martin A, et al. Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood 2006; 107:3787-3794.
41. Turner MS, Kane LP, Morel PA. Dominant role of antigen dose inCD4+Foxp3+ regulatory T cell induction and expansion. J Immunol 2009; 183:4895-4903.
42. Min WP, Gorczynski R, Huang XY, et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol 2000; 164:161-167.
43. Sun W, Wang Q, Zhang L, et al. Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin. Transplantation 2003; 76:1351-1359.
44. Wang Q, Liu Y, Wang J, et al. Induction of allospecific tolerance by immature dendritic cells genetically modified to express soluble TNF receptor. J Immunol 2006; 177:2175-2185.
45. Zhang M, Wang Q, Liu Y, et al. Effective induction of immune tolerance by portal venous infusion with IL-10 gene-modified immature dendritic cells leading to prolongation of allograft survival. J Mol Med 2004; 82:240-249.
46. Dudler J, Li J, Pagnotta M, et al. Gene transfer of programmed death ligand-1.Ig prolongs cardiac allograft survival. Transplantation 2006; 82:1733-1737.
47. Li J, Meinhardt A, Roehrich ME, et al. Indoleamine 2,3-dioxygenase gene transfer prolongs cardiac allograft survival. Am J Physiol Heart Circ Physiol 2007; 293:H3415-3423.
48. Simeoni E, Dudler J, Fleury S, et al. Gene transfer of a soluble IL-1 type 2 receptor-Ig fusion protein improves cardiac allograft survival in rats. Eur J Cardiothorac Surg 2007; 31:222-228.
49. Toscano MG, Delgado M, Kong W, et al. Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogeniclike DCs. Mol Ther 2010; 18:1035-1045.
50. Bahri R, Naji A, Menier C, et al. Dendritic cells secrete the immunosuppressive HLA-G molecule upon CTLA4-Ig treatment: implication in human renal transplant acceptance. J Immunol 2009; 183:7054-7062.
51. Tseng SY, Nishimoto KP, Silk KM, et al. Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells. Regen Med 2009; 4:513-526.
52. Zhou Z, French DL, Ma G, et al. Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells 2010; 28:620-632.
53. Belkaid Y, Oldenhove G. Tuning microenvironments: induction of regulatory T cells by dendritic cells. Immunity 2008; 29:362-371.
54. Yates SF, Paterson AM, Nolan KF, et al. Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation. J Immunol 2007; 179:967-976.
55. Gorman S, Kuritzky LA, Judge MA, et al. Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J Immunol 2007; 179:6273-6283.
56. Ghoreishi M, Bach P, Obst J, et al. Expansion of antigen-specific regulatory T cells with the topical vitamin D analog calcipotriol. J Immunol 2009; 182:6071-6078.
57. Hullett DA, Cantorna MT, Redaelli C, et al. Prolongation of allograft survival by 1,25-dihydroxyvitamin D3. Transplantation 1998; 66:824-828.
58. Szeles L, Keresztes G, Torocsik D, et al. 1,25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype. J Immunol 2009; 182:2074-2083.
59. Gregori S, Casorati M, Amuchastegui S, et al. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001; 167:1945-1953.
60. Bronte V, Chappell DB, Apolloni E, et al. Unopposed production of granulocyte- macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999; 162:5728-5737.
61. Dolcetti L, Peranzoni E, Ugel S, et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010; 40:22-35.
62. Dudziak D, Kamphorst AO, Heidkamp GF, et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007; 315:107-111.
63. Tanriver Y, Ratnasothy K, Bucy RP, et al. Targeting MHC class I monomers to dendritic cells inhibits the indirect pathway of allorecognition and the production of IgG alloantibodies leading to long-term allograft survival. J Immunol 2010; 184:1757-1764.
64. Randolph GJ, Ochando J, Partida-Sanchez S. Migration of dendritic cell subsets and their precursors. Annu Rev Immunol 2008; 26:293-316.
65. Lakkis FG, Arakelov A, Konieczny BT, Inoue Y. Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 2000; 6:686-688.
66. Reed AJ, Noorchashm H, Rostami SY, et al. Alloreactive CD4 T cell activation in vivo: an autonomous function of the indirect pathway of alloantigen presentation. J Immunol 2003; 171:6502-6509.
67. Yamazaki S, Dudziak D, Heidkamp GF, et al. CD8+CD205+splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J Immunol 2008; 181:6923-6933.
68. Garcia MR, Ledgerwood L, Yang Y, et al. Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. J Clin Invest 2010. 120:doi: 10.1172/JCI41628. [Epub ahead of print].
69. Ochando JC, Homma C, Yang Y, et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 2006; 7:652-662.
70. Dawicki W, Jawdat DW, Xu N, Marshall JS. Mast cells, histamine, and IL-6 regulate the selective influx of dendritic cell subsets into an inflamed lymph node. J Immunol 2010; 184:2116-2123.
71. Janatpour MJ, Hudak S, Sathe M, et al. Tumor necrosis factor-dependent segmental control of MIG expression by high endothelial venules in inflamed lymph nodes regulates monocyte recruitment. J Exp Med 2001; 194:1375-1384.
72. Yoneyama H, Matsuno K, Zhang Y, et al. Evidence for recruitment of plasmacytoid dendritic cell precursors to inflamed lymph nodes through high endothelial venules. Int Immunol 2004; 16:915-928.
73. Boisgerault F, Liu Y, Anosova N, et al. Differential roles of direct and indirect allorecognition pathways in the rejection of skin and corneal transplants. Transplantation 2009; 87:16-23.
74. Illigens BM, Yamada A, Anosova N, et al. Dual effects of the alloresponse by Th1 and Th2 cells on acute and chronic rejection of allotransplants. Eur J Immunol 2009; 39:3000-3009.
75. Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008; 14:88-92.
76. Sayegh MH, Weiner HL. Regulating rejection with cell therapy. Nat Biotechnol 2008; 26:191-192.